473924-63-9 Usage
Uses
Used in Pharmaceutical Industry:
2-[(TERT-BUTOXYCARBONYL)AMINO]METHYLISONICOTINIC ACID is used as a reagent for the synthesis of protein-kinase B/Akt inhibitors. These inhibitors are crucial in the development of drugs that target the Akt signaling pathway, which plays a significant role in various cellular processes, including cell survival, growth, and metabolism. By inhibiting this pathway, it is possible to develop treatments for a range of diseases, including cancer and neurodegenerative disorders.
In the synthesis of protein-kinase B/Akt inhibitors, 2-[(TERT-BUTOXYCARBONYL)AMINO]METHYLISONICOTINIC ACID contributes to the formation of the active pharmaceutical ingredient, which can then be used in the development of therapeutic agents. Its unique structure allows for the creation of compounds with specific binding properties, making it an essential component in the design and synthesis of novel drugs targeting the Akt pathway.
Check Digit Verification of cas no
The CAS Registry Mumber 473924-63-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,3,9,2 and 4 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 473924-63:
(8*4)+(7*7)+(6*3)+(5*9)+(4*2)+(3*4)+(2*6)+(1*3)=179
179 % 10 = 9
So 473924-63-9 is a valid CAS Registry Number.
473924-63-9Relevant academic research and scientific papers
COMPOUNDS AND USES THEREOF
-
Page/Page column 168, (2021/08/06)
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS
-
Page/Page column 55, (2008/06/13)
The invention relates to novel pyrimidine derivatives of Formula (I), which are efficacious inhibitors of protein kinases, in particular of one or more isoforms of the protein kinase B/Akt.
Pyrazole derivatives
-
, (2008/06/13)
This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such, the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
